![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
1. Ahr-10282
2. Bromfenac Sodium
3. Duract
4. Isv-303
5. Sodium Bromfenac
6. Xibrom
1. 91714-94-2
2. 2-(2-amino-3-(4-bromobenzoyl)phenyl)acetic Acid
3. Xibrom
4. Bromfenac [inn]
5. Bromfenaco
6. Bromfenacum
7. 2-[2-amino-3-(4-bromobenzoyl)phenyl]acetic Acid
8. Prolensa
9. 2-amino-3-(4-bromobenzoyl)benzeneacetic Acid
10. Bromday
11. Isv-303
12. [2-amino-3-(4-bromobenzoyl)phenyl]acetic Acid
13. Ahr-10282
14. Bromfenac (inn)
15. Yellox
16. 120638-55-3
17. Benzeneacetic Acid, 2-amino-3-(4-bromobenzoyl)-
18. Chebi:240107
19. Bromfenaco [spanish]
20. [2-amino-3-(4-bromo-benzoyl)-phenyl]-acetic Acid
21. Bromsite
22. 864p0921dw
23. 2-{2-amino-3-[(4-bromophenyl)carbonyl]phenyl}acetic Acid
24. Bromfenacum [latin]
25. Bromfenac Sodium Hydrate
26. Ahr-10282b
27. Sodium (2-amino-3-(4-bromobenzoyl)phenyl)acetate
28. Unii-864p0921dw
29. 4mjq
30. Ahr 10282
31. Bromfenac Acid
32. Bromfenac [mi]
33. Bromfenac [vandf]
34. Bromfenac [who-dd]
35. Chembl1077
36. Schembl34411
37. Mls004774052
38. Gtpl7131
39. {2-amino-3-[(4-bromophenyl)carbonyl]phenyl}acetic Acid
40. Dtxsid7040655
41. Hms3741c05
42. Hy-b1888
43. Vea63855
44. Zinc2570817
45. Bdbm50248104
46. Mfcd00864341
47. Akos015998697
48. Db00963
49. Gs-3830
50. Sb17362
51. Da-00968
52. Smr003500721
53. Cs-0013951
54. Ft-0710423
55. D07541
56. Benzeneacetic Acid,2-amino-3-(4-bromobenzoyl)-
57. 638b553
58. A844048
59. A906783
60. Sr-01000941476
61. J-519935
62. Q2487682
63. Sr-01000941476-2
64. Brd-k47679368-323-01-3
65. 2-[2-amino-3-(4-bromobenzoyl)phenyl]acetic Acid;2-(2-amino-3-(4-bromobenzoyl)phenyl)acetic Acid
66. 27r
Molecular Weight | 334.16 g/mol |
---|---|
Molecular Formula | C15H12BrNO3 |
XLogP3 | 3.3 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 4 |
Rotatable Bond Count | 4 |
Exact Mass | 333.00006 g/mol |
Monoisotopic Mass | 333.00006 g/mol |
Topological Polar Surface Area | 80.4 Ų |
Heavy Atom Count | 20 |
Formal Charge | 0 |
Complexity | 366 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
1 of 4 | |
---|---|
Drug Name | Bromday |
PubMed Health | Bromfenac (Into the eye) |
Drug Classes | Anti-Inflammatory |
Drug Label | Bromday (bromfenac ophthalmic solution) 0.09% is a sterile, topical, nonsteroidal anti-inflammatory drug (NSAID) for ophthalmic use. Each mL of Bromday contains 1.035 mg bromfenac sodium (equivalent to 0.9 mg bromfenac free acid). Bromfenac sodi... |
Active Ingredient | Bromfenac sodium |
Dosage Form | Solution/drops |
Route | Ophthalmic |
Strength | eq 0.09% acid |
Market Status | Prescription |
Company | Bausch And Lomb |
2 of 4 | |
---|---|
Drug Name | Prolensa |
Drug Label | PROLENSA (bromfenac ophthalmic solution) 0.07% is a sterile, topical, nonsteroidal anti-inflammatory drug (NSAID) for ophthalmic use. Each mL of PROLENSA contains 0.805 mg bromfenac sodium sesquihydrate (equivalent to 0.7 mg bromfenac free acid). The... |
Active Ingredient | Bromfenac sodium |
Dosage Form | Solution/drops |
Route | Ophthalmic |
Strength | eq 0.07% acid |
Market Status | Prescription |
Company | Bausch And Lomb |
3 of 4 | |
---|---|
Drug Name | Bromday |
PubMed Health | Bromfenac (Into the eye) |
Drug Classes | Anti-Inflammatory |
Drug Label | Bromday (bromfenac ophthalmic solution) 0.09% is a sterile, topical, nonsteroidal anti-inflammatory drug (NSAID) for ophthalmic use. Each mL of Bromday contains 1.035 mg bromfenac sodium (equivalent to 0.9 mg bromfenac free acid). Bromfenac sodi... |
Active Ingredient | Bromfenac sodium |
Dosage Form | Solution/drops |
Route | Ophthalmic |
Strength | eq 0.09% acid |
Market Status | Prescription |
Company | Bausch And Lomb |
4 of 4 | |
---|---|
Drug Name | Prolensa |
Drug Label | PROLENSA (bromfenac ophthalmic solution) 0.07% is a sterile, topical, nonsteroidal anti-inflammatory drug (NSAID) for ophthalmic use. Each mL of PROLENSA contains 0.805 mg bromfenac sodium sesquihydrate (equivalent to 0.7 mg bromfenac free acid). The... |
Active Ingredient | Bromfenac sodium |
Dosage Form | Solution/drops |
Route | Ophthalmic |
Strength | eq 0.07% acid |
Market Status | Prescription |
Company | Bausch And Lomb |
For the treatment of postoperative inflammation in patients who have undergone cataract extraction.
FDA Label
Treatment of postoperative ocular inflammation following cataract extraction in adults.
Bromfenac ophthalmic solution is a sterile, topical, nonsteroidal anti-inflammatory drug (NSAID) for ophthalmic use.
Anti-Inflammatory Agents, Non-Steroidal
Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. (See all compounds classified as Anti-Inflammatory Agents, Non-Steroidal.)
S01BC11
S - Sensory organs
S01 - Ophthalmologicals
S01B - Antiinflammatory agents
S01BC - Antiinflammatory agents, non-steroids
S01BC11 - Bromfenac
Absorption
The plasma concentration of bromfenac following ocular administration in humans is unknown.
The mechanism of its action is thought to be due to its ability to block prostaglandin synthesis by inhibiting cyclooxygenase 1 and 2. Prostaglandins have been shown in many animal models to be mediators of certain kinds of intraocular inflammation. In studies performed in animal eyes, prostaglandins have been shown to produce disruption of the blood-aqueous humor barrier, vasodilation, increased vascular permeability, leukocytosis, and increased intraocular pressure.